Previous Page  111 / 111
Information
Show Menu
Previous Page 111 / 111
Page Background

W

aldenström

s

macroglobulinemia

a

review

R

ev

A

ssoc

M

ed

B

ras

2014; 60(5):490-499

499

37.

Moyner K, Sletten K, Husby G, Natvig JB. An unusually large (83 amino

acid residues) amyloid fibril protein AA from a patient with Waldenström’s

macroglobulinaemia and amyloidosis. Scand J Immunol. 1980;11:549-54.

38.

Shah IA, Netto D, Ashfaq R, Krieger C. Waldenström’s macroglobulinemia

associated with generalized AA-amyloidosis. Int J Surg Pathol. 1993;1:123-7.

39. Gardyn J, Schwartz A, Gal R, Lewinski U, Kristt D, AM. C. Waldenström’s

macroglobulinemia associated with AA amyloidosis. Int J Hematol. 2001

74:76-8.

40.

Hunter ZR, Manning RJ, Hanzis C, Ciccarelli BT, Ioakimidis L, Patterson

CJ, et al. IgA and IgG hypogammaglobulinemia in Waldenstrom’s

macroglobulinemia. Haematologica. 2010;95:470-5.

41.

Singh A, Eckardt KU, Zimmermann A, Götz KH, Hamann M, Ratcliffe PJ,

et al. Increased plasma viscosity as a reason for inappropriate erythropoietin

formation. J Clin Invest. 1993;91:251-6.

42.

Roux S, Fermand JP, Brechignac S, Mariette X, Kahn MF, Brouet JC. Tumoral

joint involvement in multiple myeloma and Waldenström’s

macroglobulinemia -report of 4 cases. J Rheumatol. 1996;23:2175-8.

43.

Kaila VL, El-Newihi HM, Dreiling BJ, Lynch CA, Mihas AA. Waldenström’s

macroglobulinemia of the stomach presenting with upper gastrointestinal

hemorrhage. Gastrointest Endosc. 1996;44:73-5.

44. Yasui O, Tukamoto F, Sasaki N, Saito T, Yagisawa H, Uno A, et al. Malignant

lymphoma of the transverse colon associated with macroglobulinemia. Am

J Gastroenterol. 1997;92:2299-301.

45.

Rosenthal JA, Curran WJ, Schuster SJ. Waldenström’s macroglobulinemia

resulting from localized gastric lymphoplasmacytoid lymphoma. Am J

Hematol. 1998;58:244-5.

46.

Recine MA, Perez MT, Cabello-Inchausti B, Lilenbaum RC, Robinson MJ.

Extranodal lymphoplasmacytoid lymphoma (immunocytoma) presenting

as small intestinal obstruction. Arch Pathol Lab Med. 2001;125:677-9.

47.

Rausch PG, Herion JC. Pulmonary manifestations of Waldenstrom

macroglobulinemia. Am J Hematol. 1980;9:201-9.

48.

Fadil A, Taylor DE. The lung and Waldenstrom’s macroglobulinemia. South

Med J. 1998;91:681-5.

49. Veltman GA, van Veen S, Kluin-Nelemans JC, Bruijn JA, van Es LA. Renal

disease in Waldenström’s macroglobulinaemia. Nephrol Dial Transplant.

1997;12:1256-9.

50.

Mascaro JM, Montserrat E, Estrach T, Feliu E, Ferrando J, Castel T, et al.

Specific cutaneous manifestations of Waldenström’s macroglobulinemia.

A report of two cases. Br J Dermatol. 1982;106:17-22.

51. Orellana J, Friedman AH. Ocular manifestations of multiple myeloma,

Waldenström’s macroglobulinemia and benign monoclonal gammopathy.

Surv Ophthalmol. 1981;26:157-69.

52.

Ettl AR, Birbamer GG, Philipp W. Orbital involvement in Waldenström’s

macroglobulinemia: ultrasound, computed tomography and magnetic

resonance findings. Ophthalmologica. 1992;205:40-5.

53. Civit T, Coulbois S, Baylac F, Taillandier L, Auque J. Waldenström’s

macroglobulinemia and cerebral lymphoplasmocytic proliferation: Bing and

Neel syndrome. Apropos of a new case. Neurochirurgie. 1997;43:245-9.

54.

Lin P, Mansoor A, Bueso-Ramos C, Hao S, Lai R, Medeiros LJ. Diffuse large

B-cell lymphoma occurring in patients with lymphoplasmacytic lymphoma/

Waldenstrom macroglobulinemia - clinicopathologic features of 12 Cases.

Am J Clin Pathol. 2003;120:246-53.

55.

Feiner HD, Rizk CC, Finfer MD, Bannan M, Gottesman SR, Chuba JV, et al.

IgM monoclonal gammopathy/Waldenström’s macroglobulinemia: a

morphological and immunophenotypic study of the bone marrow. Mod

Pathol. 1990;3:348-56.

56.

San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sánchez-Guijo F, Sánchez

ML, et al. Immunophenotypic analysis of Waldenstrom’s macroglobulinemia.

Semin Oncol. 2003;30:187-95.

57. Pangalis G, Kyrtsonis M-C, Kontopidou F, Siakantaris M, Dimopoulou M,

Vassilakopoulos T, et al. Differential diagnosis of Waldenström’s

macroglobulinemia and other B-Cell disorders. Clin Lymphoma. 2005;5:235-40.

58.

Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et

al. A long-term study of prognosis in monoclonal gammopathy of

undetermined significance. N Engl J Med. 2002;346:564-9.

59.

Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR,

et al. Long-term follow-up of IgMmonoclonal gammopathy of undetermined

significance. Blood. 2003;102:3759-64.

60.

Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J,

et al. International prognostic scoring system for Waldenstrom

macroglobulinemia. Blood. 2009;113:4163-70.

61.

Kastritis E, Kyrtsonis MC, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis

P, et al. Validation of the International Prognostic Scoring System (IPSS)

for Waldenstrom’s macroglobulinemia (WM) and the importance of serum

lactate dehydrogenase (LDH). Leuk Res. 2010;34:1340-3.

62. TreonSP.HowItreatWaldenstrommacroglobulinemia.Blood.2009;114:2375-85.

63. Dimopoulos MA, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, LeBlond V,

et al. Update on treatment recommendations from the Fourth International

Workshop onWaldenström’s macroglobulinemia. J ClinOncol. 2009;27:120-6.

64. Vijay A, Gertz M. Current treatment options for Waldenström

macroglobulinemia. Clin Lymphoma. 2008;8:219-29.

65.

Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C,

Kokkinis G, et al. Primary treatment of Waldenström macroglobulinemia

with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol.

2007;25:3344-9.

66. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The

clinical application of monoclonal antibodies in chronic lymphocytic

leukemia. Blood. 2010;116:3705-14.

67.

Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of

action and resistance. Oncogene. 2003;22: 7359-68.

68. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E,

et al. Polymorphisms in Fc’RIIIA (CD16) receptor expression are associated

with clinical response to rituximab in Waldenström’s macroglobulinemia.

J Clin Oncol. 2005;23:474-81.

69. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, et al. Initial

immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed

with Waldenstrom macroglobulinemia. Cancer. 2004;101:2593-8.

70.

Dimopoulos MA, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki

V, et al. Treatment of Waldenström’s macroglobulinemia with rituximab. J

Clin Oncol. 2002;20:2327-33.

71. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC.

Paradoxical increases in serum IgM and viscosity levels following rituximab

in Waldenstrom’s macroglobulinemia. Ann Oncol. 2004;15:1481-3.

72.

Issa GC, Ghobrial IM, Roccaro AM. Novel agents in Waldenström

macroglobulinemia. Clin Invest (Lond). 2011;1:815-24.

73. Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, et al.

Response assessment in Waldenstrom macroglobulinaemia: update from

the 6

th

International Workshop. Br J Haematol. 2013;160:171-6.

74. Ciccarelli BT, Yang G, Hatjiharissi E, Ioakimidis L, Patterson CJ, Manning RJ,

et al. Soluble CD27 is a faithful marker of disease burden and is unaffected by

the rituximab-induced IgMflare, as well as by plasmapheresis, in patients with

Waldenstrom’s macroglobulinemia. Clin Lymphoma. 2009;09:56 AM-8.

75.

Itzykson R, Le Garff-Tavernier M, Katsahian S, Diemert MC, Musset L,

Leblond V. Serum-free light chain elevation is associated with a shorter time

to treatment in Waldenstrom’s macroglobulinemia. Haematologica.

2008;93:793-4.

76.

Fonseca R, Hayman S. Waldenström macroglobulinaemia. Br J Haematol.

2007;138:700-20.